Moxonidine canon Tab n / a film about 0.4mg 28 pc


Moxonidine canon Tab n / a film about 0.4mg 28 pc



Active substance:
1 tablet contains 0.2 mg: 0.2 mg moxonidine
1 tablet contains 0.3 mg: 0.3 mg moxonidine
1 tablet contains 0.4 mg: 0.4 mg moxonidine.
0.2 mg 1 tablet contains: giproloza (hydroxypropyl cellulose) 3 mg mannitol 68 mg Croscarmellose sodium 3.3 mg Magnesium stearate 0.5 mg Microcrystalline cellulose 25 mg; composition of the film coating: Opadry II pink 3mg, including: polyvinyl alcohol 1.2mg macrogol (polyethylene glycol) 0.606 mg Talc 0.444 mg, 0.7206 mg of titanium dioxide, dye sunset yellow 0.0003 mg, indigo dye 0.0045 mg carmine dye [Ponceau 4R] 0,0246 mg.
0.3 mg 1 tablet contains: giproloza (hydroxypropyl cellulose) 3.6 mg mannitol 81.5 mg croscarmellose sodium 4 mg Magnesium stearate 0.6 mg Microcrystalline cellulose 30 mg; composition of the film coating: Opadry II pink 3.5 mg including 1.4 mg of polyvinyl alcohol, macrogol (polyethylene glycol) 0.707 mg Talc 0.518 mg, 0.6626 mg of titanium dioxide, dye sunset yellow 0.0889 mg 0.0507 mg indigo dye, the dye Ponceau [Ponceau 4R] 0,0728 mg.
0.4 mg 1 tablet contains: giproloza (hydroxypropyl cellulose) 4.2 mg mannitol 95 mg Croscarmellose sodium 4.7 mg Magnesium stearate 0.7 mg Microcrystalline cellulose 35 mg; composition of the film coating: Opadry II pink 4 mg including 1.6 mg of polyvinyl alcohol, macrogol (polyethylene glycol) 0.808 mg Talc 0.592 mg, 0.9608 mg of titanium dioxide, dye sunset yellow 0.0004 mg, indigo dye 0.0060 mg carmine dye [Ponceau 4R] 0,0328 mg.
The tablets are round, biconvex, film-coated pink (dosage 0.2 mg and 0.4 mg) or dark pink (dosage 0.3 mg). The cross sectional almost white color. The slight roughness.
Product form:
Tablets, film-coated, 0.2 mg, 0.3 mg and 0.4 mg.
At 7, 10, 28 or 30 tablets in blisters of PVC film and aluminum foil printed patent.
At 2, 4, 6, 8, contour cell packs 7 tablets or 1, 2, 3, 4, 6 contour cell packs of 10 tablets, or 1, 2 blisters 28 tablets, or 1, 2, 3, 4 blisters with 30 tablets with instructions for use placed in a pile of cardboard.
Increased sensitivity to the drug; The expressed disturbances of heart rhythm; sick sinus syndrome; sinoatrial and atrioventricular block II and III degree; bradycardia (heart rate less than 50 beats / min); acute and chronic heart failure III and IV NYHA functional class classification; angioedema history; severe liver failure (more than 9 points on the scale ChayldPyu); chronic renal failure (creatinine clearance less than 30 mL / min, creatinine 160 umol / L); hemodialysis; simultaneous use of tricyclic antidepressants; age 18 years (effectiveness and safety have been established); age over 75 years; lactation.
Precautions Parkinson’s disease (severe); epilepsy; glaucoma; depression; “Intermittent” claudication; Raynaud’s disease; I degree atrioventricular block; chronic renal failure (creatinine clearance of more than 30 ml / min, but less than 60 ml / min); severe cerebrovascular disorders; post-myocardial infarction; severe coronary artery disease; severe coronary heart disease or unstable angina pectoris (lack of application experience); chronic heart failure I and II NYHA functional class classification; impaired liver function; pregnancy.
0.4 mg
Arterial hypertension.
Interaction with other drugs
Canon moxonidine may be administered with thiazide diuretics and blockers of the “slow” calcium channels. The combined use of the drug Moxonidine Canon with these and other antihypertensive agents leads to additive effect and increased hypotensive effect.
When administering the drug Moxonidine Canon hydrochlorothiazide, glibenclamide (glyburide) or digoxin pharmacokinetic interaction is absent.
Tricyclic antidepressants may reduce the effectiveness of centrally acting antihypertensive agents, however, their simultaneous use is not recommended.
The drug Moxonidine moderately Canon enhances cognitive decline in patients receiving lorazepam.
Use of the drug Moxonidine Canon together with benzodiazepines may be accompanied by increased sedative effect of the latter.
The drug Moxonidine Canon dampening effect on the central nervous system anxiolytics, barbiturates and ethanol.
Beta-blockers when combined with moxonidine enhance bradycardia, the severity of the negative foreign-and dromotropic action.
When administering the drug Moxonidine together with moclobemide Canon pharmacodynamic interaction is absent.
Symptoms: headache, sedation, drowsiness, and marked reduction in blood pressure, dizziness, weakness, bradycardia, increased fatigue, dryness of the oral mucosa, vomiting and stomach pain. Potentially also possible paradoxical increase in blood pressure, tachycardia, hyperglycemia.
Treatment: No specific antidote. Gastric lavage (immediately after administration), activated charcoal method and laxatives, symptomatic therapy. In case of significant decrease in blood pressure is recommended restore circulating blood volume due to fluid delivery and administration of dopamine. Bradycardia atropine may be cropped.
Alpha-adrenoreceptor antagonists can reduce or eliminate transient hypertension with Moxonidine Canon drug overdose.
pharmachologic effect
Pharmacological group:
Centrally acting antihypertensive agent.
Selective imidazoline receptor agonist is responsible for the tonic reflex and control of the sympathetic nervous system (localized in Venter-lateral medulla). Decreases pressor effect on the peripheral sympathetic system vessels reduces peripheral vascular resistance, decreases the systolic and diastolic blood pressure both at single and chronic administration, whereas cardiac output and heart rate (HR) were not significantly changed. With prolonged use reduces left ventricular hypertrophy, myocardial fibrosis eliminates the symptoms, mikroarteriopatii normalizes capillary blood supply of the myocardium. The treatment reduces the activity of norepinephrine and epinephrine, renin, angiotensin II at rest and during exercise, the atrial natriuretic peptide (under a load) and aldosterone blood plasma.
It has a lower affinity for the alpha 2-adrenergic receptors, which explains the lower probability of sedation and dry mouth.
Decreased resistance to insulin. It has no effect on glucose metabolism and lipid.
Absorption after oral administration – 90%. Food intake does not affect the absorption. Bioavailability – 88%. Communication with the plasma protein – 7.2%. The maximum concentration (Cmax) in plasma is determined by 30-180 min after oral administration and is 1-3 ng / ml. The volume of distribution – 1,4-3 l / kg. The main metabolite – dihydrogenated moxonidine. Pharmacodynamic Activity dehydrogenated moxonidine – about 10% as compared with moxonidine. It penetrates the blood-brain barrier. Not accumulates long-term use. The half-life of moxonidine and metabolites of 2.5 and 5 hours, respectively. Within 24 hours, more than 90% moxonidine excreted by the kidneys (78% – unchanged, and 13% – in the form dihydrogenated moxonidine, 8% – in the form of other metabolites). Less than 1% of the dose is excreted through the intestines. Moxonidine slightly displayed during hemodialysis.
Pharmacokinetics in patients with hypertension
In patients with hypertension is not observed changes in the pharmacokinetics of moxonidine.
Pharmacokinetics in elderly patients
It is noted clinically insignificant change in pharmacokinetic parameters moxonidine in elderly patients, probably due to decrease in the intensity of its metabolism and / or somewhat higher bioavailability.
Pharmacokinetics in renal failure
Excretion Moxonidine largely correlates with creatinine clearance (CC). In patients with moderate renal impairment (creatinine clearance in the range of 30-60 ml / min) the equilibrium concentrations in the blood and a plasma terminal half-life of approximately 2 and 1.5 times higher than those with normal renal function of patients (creatinine clearance greater than 90 mL / min ). In patients with severe renal failure (creatinine clearance less than 30 mL / min) equilibrium concentrations in plasma and terminal half-life 3 times higher than in patients with normal renal function. Patients with end-stage renal failure (creatinine clearance less than 10 mL / min) on hemodialysis, the equilibrium concentration in the blood plasma and terminal half-life, respectively, at 4 and 6 times higher than in patients with normal renal function. In patients with impaired renal function, dosage should be individualized.
Pregnancy and breast-feeding
Clinical data on the negative impact on the course of pregnancy there. However, the drug Moxonidine Canon should be administered to pregnant women only if the potential benefit to the mother outweighs the potential risk to the fetus.
Moxonidine passes into breast milk, so if the drug Moxonidine Canon necessary during lactation, breast-feeding should be discontinued.
Conditions of supply of pharmacies
side effects
Classification of the WHO frequency of side effects: very often -> 1/10 assignments (> 10%) frequently – by> 1/100 to 1%, and
special instructions
If necessary, cancel the concomitant beta-blockers and drug Moxonidine Canon, first override beta blockers and just a few days the drug Moxonidine Canon.
Not recommended for tricyclic antidepressants concurrently with the drug Moxonidine Canon.
During treatment requires regular monitoring of blood pressure, heart rate and ECG.
The drug may be administered Canon Moxonidine with thiazide diuretics, angiotensin-converting enzyme (ACE) blockers and “slow” calcium channels.
Stop taking the drug Moxonidine Canon should be gradual.
Effect on the ability to drive mechanisms and
Taking into account the possible occurrence of drowsiness and dizziness during treatment with Moxonidine Canon patients should be careful during the occupation of potentially hazardous activities that require attention, such as driving a vehicle or control technique, which requires high concentration of attention.
Storage conditions
In a dry, dark place at a temperature not higher than 25 C. Keep out of reach of children.
Dosing and Administration
Inside, regardless of food intake, drinking plenty of fluids. In most cases, the initial dose of the drug Moxonidine Canon 0.2 mg per day, in one portion, preferably in the morning. When insufficient therapeutic effect of the dose can be increased after 3 weeks of therapy to 0.4 mg per day, which should be divided into 2 doses (morning and evening), or once.
The maximum daily dose to be divided into 2 doses (morning and evening), is 0.6 mg. The maximum single dose is 0.4 mg.
In elderly patients with normal renal function, dosage recommendations are the same as for adult patients.
In patients with renal failure (creatinine clearance of 30-60 ml / min) and patients on hemodialysis single dose should not exceed 0.2 mg, the maximum daily dose – 0.4 mg.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review